{"schema_version":"secwatch.filing_event.v1","accession":"0001798749-23-000037","form_type":"8-K","ticker":"JBIO","cik":"0001798749","company_name":"Jade Biosciences, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.643511+00:00","generated_at":"2026-06-15T01:25:27.178756+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aerovate Therapeutics Q1 net loss $16.5M; Phase 2b topline data pushed to Q2 2024","bullets":["Topline Phase 2b data from IMPAHCT trial of AV-101 now expected in Q2 2024; >100 sites in 20 countries.","Cash, equivalents and short-term investments $118.9M at March 31, 2023; runway into H2 2025.","Net loss $16.5M for Q1 2023 vs $10.9M Q1 2022; R&D expenses $13.5M (up from $7.3M).","Enrollment pace increasing but slower than expected due to post-COVID factors."],"urls":{"canonical":"https://secwatch.observer/filing/0001798749-23-000037","json":"https://secwatch.observer/filing/0001798749-23-000037.json","markdown":"https://secwatch.observer/filing/0001798749-23-000037.md","text":"https://secwatch.observer/filing/0001798749-23-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000179874923000037/0001798749-23-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000179874923000037/tmb-20230515x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:25:27.178756+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"850de88ef3d9afb998b79d38cc4e7727f3ffa7d7","claim":"Jade Biosciences, Inc. reported first quarter 2023 results: net income -$16.5 million.","evidence_excerpt":"Net loss for the first quarter ended March 31, 2023 was $16.5 million as compared to $10.9 million for the first quarter ended March 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1798749/000179874923000037/0001798749-23-000037-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2023"},{"label":"Net income","value":"-$16.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}